Lassila & Tikanoja Plc Earnings Missed Analyst Estimates: Here’s What Analysts Are Forecasting Now

Nov 2, 2026
lassila-&-tikanoja-plc-earnings-missed-analyst-estimates:-here’s-what-analysts-are-forecasting-now

Investors in Lassila & Tikanoja Plc (HEL:LASTIK) had a good week, as its shares rose 4.1% to close at €6.28 following the release of its quarterly results. It looks like the results were a bit of a negative overall. While revenues of €118m were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 7.7% to hit €0.24 per share. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

earnings-and-revenue-growth
HLSE:LASTIK Earnings and Revenue Growth November 2nd 2026

Taking into account the latest results, the most recent consensus for Lassila & Tikanoja from three analysts is for revenues of €454.8m in 2027. If met, it would imply a reasonable 3.5% increase on its revenue over the past 12 months. Per-share earnings are expected to leap 65% to €0.74. Yet prior to the latest earnings, the analysts had been anticipated revenues of €455.2m and earnings per share (EPS) of €0.75 in 2027. The consensus analysts don’t seem to have seen anything in these results that would have changed their view on the business, given there’s been no major change to their estimates.

See our latest analysis for Lassila & Tikanoja

With no major changes to earnings forecasts, the consensus price target fell 9.5% to €7.60, suggesting that the analysts might have previously been hoping for an earnings upgrade. There’s another way to think about price targets though, and that’s to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Lassila & Tikanoja analyst has a price target of €8.30 per share, while the most pessimistic values it at €7.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It’s clear from the latest estimates that Lassila & Tikanoja’s rate of growth is expected to accelerate meaningfully, with the forecast 2.8% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 1.5% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.3% per year. So it’s clear that despite the acceleration in growth, Lassila & Tikanoja is expected to grow meaningfully slower than the industry average.

The Bottom Line

The most obvious conclusion is that there’s been no major change in the business’ prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Lassila & Tikanoja’s future valuation.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year’s earnings. At Simply Wall St, we have a full range of analyst estimates for Lassila & Tikanoja going out to 2028, and you can see them free on our platform here..

And what about risks? Every company has them, and we’ve spotted 3 warning signs for Lassila & Tikanoja you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)

• Undervalued Small Caps with Insider Buying

• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Leave a comment